Share
While most organizations would have found 2020 a challenging year, the Endocrine Society’s Adrenal and Pituitary Special Interest Group managed to thrive with the help of new technology, expert staff guidance, and a group of determined members. The Endocrine Society’s Adrenal and Pituitary Special Interest Group (AP-SIG) was created to connect physicians and scientists...
Share
Even through a screen, you could feel the inescapable energy and excitement of more than 7,000 endocrinologists gathered for ENDO 2021 in March. After weathering a year of the COVID-19 pandemic, we cherished the opportunity to share knowledge and network with our professional community more than ever. ENDO 2021 drew one of our largest meeting...
Share
Drawing on years of prior research, a new paper published recently in The Journal of Clinical Endocrinology & Metabolism makes the case for a wider classification of a complex disease such as type 2 diabetes. A new series of subsets would take into account race, age at onset, and a host of other contributing factors....
Share
Researchers are exploring the complex, push-pull relationship between COVID-19 and diabetes. Is the virus truly the cause of a new type of diabetes or is it merely hastening an inevitable development in susceptible patients? From the earliest days of the COVID-19 pandemic, its effects on glycemic control have been among its challenges. Patients with...
Share
A recent Chinese study published in The Journal of Clinical Endocrinology & Metabolism seems to show that body mass index and waistline measurements do not tell the whole story when determining cardiometabolic risk factors in some ethnic groups. According to the Hormone Health Network, as of January 2020, more than 2 billion adults have obesity...
Share
Earlier this week Diabetes Care published results from a Phase 3 trial evaluating dasiglucagon for the treatment of severe hypoglycemia in adults with diabetes. Zealand Pharma is marketing the drug as Zegalogue. The study found that dasiglucagon administration resulted in a reversal of hypoglycemia (with a median recovery time of 10 minutes) with 99% of...
Share
Robert J. Lefkowitz, MD, first got into research because of the Vietnam War. As described in his new book A Funny Thing Happened on the Way to Stockholm: The Adrenaline-Fueled Adventures of an Accidental Scientist, he joined the United States Public Health Service (USPHS) to avoid being sent to Vietnam as a military doctor in...
Share
Moving is always stressful. Just imagine factoring in social distancing protocols, adhering to California’s earthquake safety standards, and pausing your research to get it done. Joy Y. Wu, MD, PhD, talks to Endocrine News about moving her research lab at Stanford University under less-than-ideal circumstances but she and her team got it done with a...
